The group’s principle activity is to conduct genetic-based, breast cancer risk test that incorporates both individualized genetic-based SNPs and personal history measures to arrive at an estimate of a woman’s breast cancer risk. The group’s products include Intergenetics(R) and Oncovue(R). The group operates from United States.
